LEXICON PHARMACEUTICALS, INC.
LXRX · NASDAQ
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications.
ESG Scores
Overall ESG3.6
Environmental5.6
Social4.0
Governance4.0
Gender Diversity
Female Directors0.11109999999999999%
Female Executives0.08321775312066575%
CEO GenderMale
Market Data
Price$1.84-0.03 (-1.60%)
Market Cap$792M
P/E Ratio—
EPS$—
52W High$1.95
52W Low$0.48
Beta1.09